Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 68CNS 7Sarcoma 5Genitourinary 3Dermatologic 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Breast 2Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 208Carcinoid Tumor 26Neoplasms 22Pancreatic Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 14Carcinoma, Neuroendocrine 11Carcinoma 11Adenoma, Islet Cell 11Neoplasm Metastasis 10Colorectal Neoplasms 9Lung Neoplasms 8Serotonin Syndrome 7Prostatic Neoplasms 7Adenocarcinoma 7Pheochromocytoma 6Gastrointestinal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Somatostatinoma 5Neuroblastoma 5Melanoma 5Gastroenteropancreatic Neuroendocrine Tumors 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Vipoma 4Sarcoma 4Rectal Neoplasms 4Paraganglioma 4

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pituitary Neoplasms × NET × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡